Lung
- Pulmonary Fibrosis Foundation
- Coalition for Pulmonary Fibrosis
- National Institutes of Health
- American College of Chest Physicians
“"Fibrosis - the replacement of healthy tissue with scar tissue – is the fundamental common pathology behind many of the deadliest and most costly diseases in the U.S., including congestive heart failure, liver cirrhosis, and diabetic nephropathy. Treatment options for these diseases are quite limited today: there are currently no FDA approved anti-fibrotic drugs, and transplant is often the option of last resort. Promedior’s goal is to develop pioneering new therapies to prevent and treat this deadly pathology, and thus improve the lives of millions of suffering people. The company’s vision is enabled by unparalleled understanding of the complex biology of fibrosis, a comprehensive patent portfolio, and a talented team of scientists and business executives dedicated to the task. ”